HCRN GU16-260: Nivolumab and salvage nivolumab ipilimumab in treatment-naïve patients with advanced renal cell carcinoma
Published: 12 Jun 2020
Views: 104
Dr Elizabeth Plimack - Fox Chase Cancer Center, Philadelphia, USA
Dr Elizabeth Plimack talks to ecancer in an online interview for the ASCO virtual meeting 2020 about the HCRN: GU16-260 study.
This was a phase II study of nivolumab and salvage nivolumab ipilimumab in treatment-naïve patients with advanced renal cell carcinoma.
Dr Plimack outlines the reasoning behind the study, and the results which showed a lack of response from the addition of ipilimumab.
Related Videos
IMvigor130: Atezolizumab with or without chemotherapy in metastatic urothelial c...
Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA
30 Jun 2020
Phase II data from the KarMMa trial for relapsed/refractory multiple myeloma
Dr Nikhil Munshi - Dana Farber Cancer Institute, Boston, USA
16 Jun 2020
OPTIC: A dose-ranging study of 3 starting doses of ponatinib for chronic-phase c...
Prof Jorge Cortes - Augusta University, Augusta, USA
13 Jun 2020
Investigating KRd versus KTd in NDMM patients with high-risk cytogenetics
Prof Heinz Ludwig - Wilhelmeninen Cancer Research Institute, Vienna, Austria
13 Jun 2020
CANDOR trial design: Investigating KdD versus Kd in relapsed/refractory multiple...
Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, German...
13 Jun 2020
CANDOR updated results: KdD versus Kd in patients with RRMM according to prior l...
Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, German...
13 Jun 2020
Updated results from KEYNOTE-426 for metastatic kidney cancer
Dr Elizabeth Plimack - Fox Chase Cancer Center, Philadelphia, USA
12 Jun 2020
Comment: JAVELIN-100 for metastatic urothelial cancer
Dr Elizabeth Plimack - Fox Chase Cancer Center, Philadelphia, USA
12 Jun 2020
Teclistamab for patients with heavily pretreated relapsed or refractory multiple...
Dr Saad Usmani - Levine Cancer Institute, Charlotte, USA
1 Jun 2020
